LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.71 | $0 | -$38M |
| 2026 Q1 | -0.67 | $0 | -$23M |
| 2025 Q4 | -0.45 | $0 | -$18M |
| 2025 Q3 | -0.14 | $0 | -$3M |
| 2025 Q2 | -20.21 | $0 | -$6M |
| 2025 Q1 | -20.21 | $0 | -$8M |
| 2024 Q3 |
| -0.63 |
| $0 |
| -$22M |
| 2024 Q2 | -7.82 | $0 | -$16M |